Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FOLD Amicus Therapeutics, Inc. daily Stock Chart
FOLD [NASD]
Amicus Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.73 Insider Own0.40% Shs Outstand187.24M Perf Week-10.92%
Market Cap2.52B Forward P/E- EPS next Y-0.87 Insider Trans92.03% Shs Float187.18M Perf Month-14.59%
Income-127.90M PEG- EPS next Q-0.28 Inst Own- Short Float13.58% Perf Quarter-18.72%
Sales63.60M P/S39.63 EPS this Y47.70% Inst Trans-0.10% Short Ratio12.22 Perf Half Y-14.97%
Book/sh2.98 P/B4.52 EPS next Y26.30% ROA-39.00% Target Price21.25 Perf Year6.83%
Cash/sh2.88 P/C4.68 EPS next 5Y- ROE-63.40% 52W Range12.04 - 17.62 Perf YTD-6.46%
Dividend- P/FCF- EPS past 5Y6.20% ROI-21.70% 52W High-25.79% Beta1.31
Dividend %- Quick Ratio10.70 Sales past 5Y14.90% Gross Margin84.00% 52W Low8.60% ATR0.69
Employees325 Current Ratio10.90 Sales Q/Q195.80% Oper. Margin- RSI (14)30.23 Volatility5.78% 4.52%
OptionableYes Debt/Eq0.30 EPS Q/Q2.60% Profit Margin- Rel Volume1.25 Prev Close13.46
ShortableYes LT Debt/Eq0.30 EarningsAug 07 BMO Payout- Avg Volume2.08M Price13.07
Recom1.70 SMA20-11.74% SMA50-15.67% SMA200-11.74% Volume501,741 Change-2.86%
Aug-17-18Downgrade Chardan Capital Markets Buy → Neutral $18 → $15
Oct-06-17Resumed Goldman Neutral
Sep-13-17Reiterated Chardan Capital Markets Buy $17.50 → $16.50
Aug-10-17Reiterated Chardan Capital Markets Buy $12.50 → $17.50
Jan-24-17Upgrade Robert W. Baird Neutral → Outperform $7 → $10
May-18-16Initiated BofA/Merrill Buy $10
Apr-14-16Initiated Robert W. Baird Neutral $9
Apr-12-16Reiterated Chardan Capital Markets Buy $10 → $15
Sep-16-15Downgrade Chardan Capital Markets Buy → Neutral $17
Jun-16-15Reiterated Chardan Capital Markets Buy $14 → $17.50
May-29-15Initiated Chardan Capital Markets Buy $14
Dec-20-12Reiterated Canaccord Genuity Buy $11 → $6
Dec-20-12Downgrade Capstone Investments Buy → Hold $3
Nov-01-12Initiated Capstone Investments Buy $7
Apr-06-10Initiated Canaccord Adams Buy
Mar-31-10Initiated Leerink Swann Mkt Perform
Oct-05-09Downgrade Wedbush Morgan Outperform → Underperform $17 → $3.50
Mar-20-09Initiated Wedbush Morgan Buy $17
Feb-27-09Reiterated Lazard Capital Buy $18 → $15
Jul-23-08Reiterated Lazard Capital Buy $13 → $21
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga -6.78%
10:16AM  Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold Zacks
09:04AM  Amicus sets $315,000 price for new Fabry disease treatment Reuters
08:28AM  Amicus sets $315,000 price for new Fabry disease treatment Reuters
Aug-12-18 04:52PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga
Aug-10-18 05:50PM  Amicus Therapeutics receives U.S. approval for Fabry disease drug Reuters
04:05PM  FDA Approves Galafold (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease GlobeNewswire
Aug-07-18 09:20AM  Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks +7.28%
08:17AM  Amicus Therapeutics: 2Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
06:30AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 03:35PM  Q2 Earnings Outlook For Amicus Therapeutics Benzinga
Jul-31-18 07:40AM  Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines Future Expectations, Projections Moving into 2018 GlobeNewswire
07:30AM  Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-30-18 08:00AM  Research Report Identifies General Dynamics, General Motors, Amicus Therapeutics, Drive Shack, Zoe's Kitchen, and Vishay Intertechnology with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Stock Performance Review on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
Jun-29-18 07:25AM  Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks ACCESSWIRE
Jun-27-18 11:32AM  All You Need To Know About Amicus Therapeutics Incs (NASDAQ:FOLD) Financial Health Simply Wall St.
08:14AM  Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics ACCESSWIRE
Jun-26-18 04:05PM  Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease GlobeNewswire
Jun-08-18 07:00AM  Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors GlobeNewswire
Jun-01-18 07:00AM  Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference GlobeNewswire
May-30-18 12:00AM  Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan GlobeNewswire +7.93%
May-25-18 08:30AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed ACCESSWIRE
May-24-18 01:55PM  Netflix, McKesson, Amicus Therapeutics, Microsoft & Micro... CNBC Videos +5.08%
May-23-18 07:00AM  Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks ACCESSWIRE
May-16-18 08:20AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics ACCESSWIRE +9.18%
May-14-18 12:39PM  Edited Transcript of FOLD earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 07:30AM  Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
May-08-18 11:47AM  When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)? Simply Wall St. -6.92%
08:57AM  Amicus Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
Apr-26-18 07:30AM  Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-20-18 08:37AM  Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options Zacks
Apr-17-18 07:30AM  Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day GlobeNewswire
Apr-16-18 07:55AM  Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-30-18 08:00AM  [$$] 3 Biotech Stocks a Pro Is Buying Now Barrons.com
Mar-22-18 09:30PM  Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan GlobeNewswire
Mar-09-18 08:15AM  Research Report Identifies Rayonier, Gannett Co., CBIZ, Amicus Therapeutics, Iamgold, and Urban Outfitters with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-05-18 07:30AM  Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018 GlobeNewswire
Mar-01-18 08:30AM  Todays Research Reports on Trending Tickers: Gilead Sciences and Amicus Therapeutics ACCESSWIRE
12:16AM  Edited Transcript of FOLD earnings conference call or presentation 28-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-18 07:00AM  Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates GlobeNewswire -9.11%
06:30AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-27-18 04:01PM  Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change Peoples Lives Living with Rare Diseases GlobeNewswire
Feb-25-18 03:50PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-21-18 04:30PM  Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock GlobeNewswire
07:30AM  Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018 GlobeNewswire
Feb-15-18 07:00PM  Amicus Therapeutics Prices Underwritten Offering of Common Stock GlobeNewswire
Feb-14-18 04:01PM  Amicus Therapeutics Announces Public Offering of Common Stock GlobeNewswire +7.25%
07:30AM  Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 04:01PM  Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-12-18 07:30AM  U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease GlobeNewswire
Feb-07-18 04:01PM  Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium GlobeNewswire
Jan-31-18 11:02AM  Best Growth Stock in January Simply Wall St.
Jan-30-18 08:20AM  Todays Research Reports on Trending Tickers: Geron Corporation and Amicus Therapeutics, Inc. ACCESSWIRE
Jan-29-18 07:30AM  Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold (migalastat) for Fabry Disease in Canada GlobeNewswire
Jan-27-18 02:00PM  2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs TheStreet.com
Jan-26-18 01:14AM  [$$] The Tax Law, Just One Month Old, Is Roaring Through U.S. Companies The Wall Street Journal
Jan-22-18 04:01PM  Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium 2018 GlobeNewswire
Jan-17-18 04:01PM  Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Spain GlobeNewswire
Jan-11-18 08:56AM  Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher Zacks
Jan-10-18 01:59PM  Lincoln National, Sears, Hasbro, Steris & Amicus Therapeu... CNBC Videos +9.15%
Jan-08-18 08:10AM  Todays Research Reports on Trending Tickers: Amicus Therapeutics, Inc. and Synergy Pharmaceuticals, Inc. ACCESSWIRE -6.37%
07:30AM  Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance GlobeNewswire
Dec-31-17 11:02AM  January Growth Opportunities Athenex And More Simply Wall St.
Dec-29-17 06:00AM  3 Small Biotechs With Big Upside Investopedia
Dec-28-17 12:08PM  ETFs with exposure to Amicus Therapeutics, Inc. : December 28, 2017 Capital Cube
Dec-21-17 07:30AM  Amicus Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-17 10:35AM  This Tiny Biotech Pins Hope on U.S. Approval Motley Fool
Dec-14-17 07:30AM  Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease GlobeNewswire
Dec-05-17 12:50PM  ETFs with exposure to Amicus Therapeutics, Inc. : December 5, 2017 Capital Cube
Dec-01-17 08:32AM  Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017 Capital Cube
Nov-29-17 07:50AM  Analysis: Positioning to Benefit within Cummins, Macy's, Twenty-First Century Fox, Amicus Therapeutics, Crocs, and Rand Logistics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-17-17 08:10AM  Todays Research Reports on Stocks to Watch: ARCA biopharma and Amicus Therapeutics ACCESSWIRE
07:20AM  Featured Company News - Sangamo Announced Treatment of First Patient in Phase-1/2 Clinical Trial Evaluating In Vivo Genome Editing Therapy for MPS II ACCESSWIRE
Nov-14-17 07:44AM  Edited Transcript of FOLD earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 11:02AM  November Top Growth Companies Simply Wall St.
Nov-08-17 12:29PM  Is It Time To Buy Amicus Therapeutics Inc (FOLD)? Simply Wall St. -7.32%
07:31AM  Amicus Therapeutics reports 3Q loss Associated Press
07:00AM  Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates GlobeNewswire
06:40AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 11:12AM  Amicus Therapeutics, Inc. Value Analysis (NASDAQ:FOLD) : November 7, 2017 Capital Cube
08:34AM  Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings? Zacks
Nov-06-17 07:18AM  Amicus Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FOLD-US : November 6, 2017 Capital Cube
Oct-25-17 07:30AM  Amicus Therapeutics to Announce Third Quarter 2017 Financial Results on November 8, 2017 GlobeNewswire
Oct-23-17 08:32AM  Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : October 23, 2017 Capital Cube
Oct-10-17 09:00PM  These Biotech Stocks Are Pricey, but Investors Can Still Buy Them Motley Fool
Oct-06-17 07:30AM  Amicus Therapeutics Appoints Michael C. Diem, MD as Senior Vice President of Business and Corporate Development GlobeNewswire -5.76%
Oct-05-17 11:10AM  Harry Boxers four stocks that are breaking out this week MarketWatch
08:51AM  Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics and CytomX Therapeutics ACCESSWIRE
Oct-04-17 04:43PM  Why These Biotechs Are Leading The Group Near A 21-Month High Investor's Business Daily +9.21%
12:38PM  Evidence of Biotech Froth Continues to Mount Bloomberg
09:59AM  There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program Benzinga
06:00AM  Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society GlobeNewswire
Oct-02-17 12:08PM  Weekly CEO Buys Highlights GuruFocus.com
Sep-21-17 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Opko Health ACCESSWIRE +5.76%
07:30AM  U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease GlobeNewswire
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Andrews Kurt J.SVP, Human ResourcesJul 02Option Exercise6.135,00030,65040,469Jul 05 04:25 PM
Baird William D IIIChief Financial OfficerJul 02Option Exercise2.4510,00024,500117,622Jul 05 04:27 PM
Baird William D IIIChief Financial OfficerJul 02Sale15.6310,000156,292107,622Jul 05 04:27 PM
Andrews Kurt J.SVP, Human ResourcesJul 02Sale15.635,00078,16635,469Jul 05 04:25 PM
Do HungChief Science OfficerJun 01Sale16.7225,000418,000396,771Jun 04 05:18 PM
MCGLYNN MARGARET GDirectorMay 16Option Exercise3.3210,00033,20025,814May 18 06:07 PM
Do HungChief Science OfficerMay 16Sale15.0025,000375,000421,771May 16 06:22 PM
MCGLYNN MARGARET GDirectorMay 16Sale16.0010,000160,00015,814May 18 06:07 PM
Barth JayChief Medical OfficerMay 14Option Exercise2.295,00011,45090,409May 15 07:37 PM
Barth JayChief Medical OfficerMay 14Sale14.045,00070,22385,409May 15 07:37 PM
Do HungChief Science OfficerApr 17Sale15.0050,000750,000446,771Apr 19 06:03 PM
RAAB MICHAELDirectorApr 16Option Exercise10.535,00052,65010,814Apr 18 06:03 PM
RAAB MICHAELDirectorApr 16Sale14.415,00072,0585,814Apr 18 06:03 PM
Barth JayChief Medical OfficerApr 12Option Exercise2.295,00011,45090,409Apr 16 05:31 PM
Barth JayChief Medical OfficerApr 12Sale14.725,00073,60285,409Apr 16 05:31 PM
Baird William D IIIChief Financial OfficerApr 02Option Exercise2.4510,00024,500127,662Apr 04 05:38 PM
Andrews Kurt J.SVP, Human ResourcesApr 02Option Exercise6.135,00030,65045,469Apr 04 05:39 PM
Andrews Kurt J.SVP, Human ResourcesApr 02Sale14.275,00071,34340,469Apr 04 05:39 PM
Baird William D IIIChief Financial OfficerApr 02Sale14.2610,000142,648117,622Apr 04 05:38 PM
Barth JayChief Medical OfficerMar 12Option Exercise2.295,00011,45090,409Mar 13 06:41 PM
Barth JayChief Medical OfficerMar 12Sale15.055,00075,25385,409Mar 13 06:41 PM
Quimi DaphneSVP, FinanceMar 09Option Exercise5.968,75052,15073,082Mar 12 06:04 PM
Quimi DaphneSVP, FinanceMar 09Sale15.008,750131,25064,332Mar 12 06:04 PM
PERCEPTIVE ADVISORS LLC10% OwnerMar 05Buy13.56335,8274,553,81418,424,424Mar 07 05:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerMar 02Buy13.90100,0001,389,50018,088,597Mar 06 04:22 PM
Quimi DaphneSVP, FinanceMar 01Option Exercise4.168,14933,90072,481Mar 05 05:55 PM
PERCEPTIVE ADVISORS LLC10% OwnerMar 01Buy13.69100,0001,369,00017,988,597Mar 05 04:37 PM
Quimi DaphneSVP, FinanceMar 01Sale14.068,149114,53764,332Mar 05 05:55 PM
Barth JayChief Medical OfficerJan 23Option Exercise2.2920,00045,800105,409Jan 25 04:16 PM
Barth JayChief Medical OfficerJan 23Sale16.8020,000336,00085,409Jan 25 04:16 PM
Campbell Bradley LChief Operating OfficerJan 22Option Exercise10.2132,500331,825186,600Jan 24 05:59 PM
Campbell Bradley LChief Operating OfficerJan 22Sale15.9232,500517,371154,100Jan 24 05:59 PM
HAYDEN DONALD J JRDirectorJan 02Option Exercise15.0020,000300,00225,814Jan 04 05:08 PM
Quimi DaphneSVP, FinanceJan 02Option Exercise14.728,000117,72362,676Jan 04 05:10 PM
Barth JayChief Medical OfficerJan 02Option Exercise14.715,00073,55969,184Jan 04 05:12 PM
Baird William D IIIChief Financial OfficerJan 02Option Exercise14.7210,000147,181105,121Jan 04 05:11 PM
RAAB MICHAELDirectorJan 02Option Exercise15.009,366140,49015,180Jan 04 05:14 PM
Andrews Kurt J.SVP, Human ResourcesJan 02Option Exercise14.7210,000147,19144,737Jan 04 05:13 PM
Andrews Kurt J.SVP, Human ResourcesJan 02Sale14.7210,000147,19134,737Jan 04 05:13 PM
RAAB MICHAELDirectorJan 02Sale15.009,366140,4905,814Jan 04 05:14 PM
Baird William D IIIChief Financial OfficerJan 02Sale14.7210,000147,18195,121Jan 04 05:11 PM
Barth JayChief Medical OfficerJan 02Sale14.715,00073,55964,184Jan 04 05:12 PM
Quimi DaphneSVP, FinanceJan 02Sale14.728,000117,72354,676Jan 04 05:10 PM
HAYDEN DONALD J JRDirectorJan 02Sale15.0020,000300,0025,814Jan 04 05:08 PM
Crowley John FChairman & CEODec 29Option Exercise14.755,92087,320333,921Jan 02 06:00 PM
Crowley John FChairman & CEODec 29Sale14.755,92087,320328,001Jan 02 06:00 PM
Crowley John FChairman & CEODec 28Option Exercise14.7513,050192,497341,051Jan 02 06:00 PM
Crowley John FChairman & CEODec 28Sale14.7513,050192,497328,001Jan 02 06:00 PM
Crowley John FChairman & CEODec 21Option Exercise13.515066,836358,507Dec 21 05:19 PM
Crowley John FChairman & CEODec 21Sale13.515066,836328,001Dec 21 05:19 PM
Crowley John FChairman & CEODec 20Option Exercise13.5165,075878,929393,076Dec 21 05:19 PM
Crowley John FChairman & CEODec 20Sale13.5165,075878,929328,001Dec 21 05:19 PM
Crowley John FChairman & CEODec 11Option Exercise13.5212,206164,973340,207Dec 13 05:13 PM
Crowley John FChairman & CEODec 11Sale13.5212,206164,973328,001Dec 13 05:13 PM
Crowley John FChairman & CEODec 04Option Exercise13.6147,213642,734375,214Dec 06 05:46 PM
Crowley John FChairman & CEODec 04Sale13.6147,213642,734328,001Dec 06 05:46 PM
Barth JayChief Medical OfficerDec 01Option Exercise13.595,00067,93769,184Dec 05 08:45 PM
Barth JayChief Medical OfficerDec 01Sale13.595,00067,93764,184Dec 05 08:45 PM
Crowley John FChairman & CEOOct 18Option Exercise14.7619,013280,544347,014Oct 19 09:33 PM
Crowley John FChairman & CEOOct 18Sale14.7619,013280,544328,001Oct 19 09:33 PM
Crowley John FChairman & CEOOct 17Option Exercise14.7552,722777,650380,723Oct 19 09:33 PM
Crowley John FChairman & CEOOct 17Sale14.7552,722777,650328,001Oct 19 09:33 PM
Crowley John FChairman & CEOOct 16Option Exercise14.7547,135695,241375,136Oct 16 09:06 PM
Crowley John FChairman & CEOOct 16Sale14.7547,135695,241328,001Oct 16 09:06 PM
Crowley John FChairman & CEOOct 13Option Exercise14.7522,160326,867350,161Oct 16 09:06 PM
Crowley John FChairman & CEOOct 13Sale14.7522,160326,867328,001Oct 16 09:06 PM
Crowley John FChairman & CEOOct 12Option Exercise14.25380,0005,414,810708,001Oct 16 09:06 PM
Quimi DaphneSVP, FinanceOct 12Option Exercise14.257,00099,74061,676Oct 16 09:07 PM
RAAB MICHAELDirectorOct 12Option Exercise14.2510,000142,53415,814Oct 16 09:10 PM
Do HungChief Science OfficerOct 12Option Exercise14.2550,194715,360523,401Oct 16 09:12 PM
Barth JayChief Medical OfficerOct 12Option Exercise14.255,00071,26869,184Oct 16 09:24 PM
Baird William D IIIChief Financial OfficerOct 12Option Exercise14.2540,000570,132135,121Oct 16 09:33 PM
Baird William D IIIChief Financial OfficerOct 12Sale14.2540,000570,13295,121Oct 16 09:33 PM
Barth JayChief Medical OfficerOct 12Sale14.255,00071,26864,184Oct 16 09:24 PM
Do HungChief Science OfficerOct 12Sale14.2550,194715,360473,207Oct 16 09:12 PM
RAAB MICHAELDirectorOct 12Sale14.2510,000142,5345,814Oct 16 09:10 PM
Quimi DaphneSVP, FinanceOct 12Sale14.257,00099,74054,676Oct 16 09:07 PM
Crowley John FChairman & CEOOct 12Sale14.25380,0005,414,810328,001Oct 16 09:06 PM
Crowley John FChairman & CEOSep 26Buy14.361,39520,032328,001Sep 28 07:34 PM
open in yahoo | open in reuters | open in google